Morgan Stanley Maintains Overweight on Cabaletta Bio, Raises Price Target to $20

Benzinga | Jul 15, 2020 10:05 AM EDT

Morgan Stanley Maintains Overweight on Cabaletta Bio, Raises Price Target to $20

Morgan Stanley maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $19 to $20.